Log in to save to my catalogue

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 random...

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 random...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3002766

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

About this item

Full title

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Publisher

London: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.32-38

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

Objectives Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, for ‘RAndomized, double-blind, Placebo-controlled st...

Alternative Titles

Full title

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3002766

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3002766

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/ard.2010.130658

How to access this item